Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 21811 [2017-09450]
Download as PDF
Federal Register / Vol. 82, No. 89 / Wednesday, May 10, 2017 / Notices
Note: The yarn size designations describe
a range of yarn specifications for yarn before
knitting, dyeing and finishing of the fabric.
They are intended as specifications to be
followed by the mill in sourcing yarn used
to produce the fabric. Dyeing, finishing and
knitting can alter the characteristic of the
yarn as it appears in the finished fabric. This
specification therefore includes yarn sizes
provided that the variation occurs after
processing of the greige yarn and production
of the fabric. The specifications for the fabric
apply to the fabric itself prior to cutting and
sewing of the finished garment. Such
processing may alter the measurements.
Terry Labat,
Acting Chairman, Committee for the
Implementation of Textile Agreements.
[FR Doc. 2017–09430 Filed 5–9–17; 8:45 am]
BILLING CODE 3510–DR–P
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary
Advisory Panel; Notice of Federal
Advisory Committee Meeting
Assistant Secretary of Defense
(Health Affairs), Department of Defense.
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The Department of Defense
(DoD) is publishing this notice to
announce that the following Federal
Advisory Committee meeting of the
Uniform Formulary Beneficiary
Advisory Panel will take place.
DATES: Open to the public Thursday,
June 22, 2017 from 9:00 a.m. to 12:00
p.m.
SUMMARY:
The address of the open
meeting is Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW.,
Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT:
Edward Norton, 703–681–2890 (Voice),
703–681–1940 (Facsimile),
dha.ncr.health-it.mbx.baprequests@
mail.mil (Email). Mailing address is
7700 Arlington Boulevard, Suite 5101,
Falls Church, VA 22042–5101. Web site:
https://www.health.mil/About-MHS/
Other-MHS-Organizations/BeneficiaryAdvisory-Panel. The most up-to-date
changes to the meeting agenda can be
found on the Web site.
SUPPLEMENTARY INFORMATION: This
meeting is being held under the
provisions of the Federal Advisory
Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the
Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and
41 CFR 102–3.140 and 102–3.150.
jstallworth on DSK7TPTVN1PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
15:21 May 09, 2017
Jkt 241001
Purpose of the Meeting: The
Department of Defense is publishing
this notice to announce a Federal
Advisory Committee meeting of the
Uniform Formulary Beneficiary
Advisory Panel (hereafter referred to as
the Panel).
Agenda:
1. Sign-In.
2. Welcome and Opening Remarks.
3. Public Citizen Comments.
4. Scheduled Therapeutic Class
Reviews (Comments will follow each
agenda item).
a. Ophthalmic-1 Agents.
b. Pulmonary Miscellaneous.
5. Newly Approved Drugs Review.
6. Pertinent Utilization Management
Issues.
7. Panel Discussions and Vote.
Meeting Accessibility: Pursuant to 5
U.S.C. 552b, as amended, and 41 Code
of Federal Regulations (CFR) 102–3.140
through 102–3.165, and the availability
of space, this meeting is open to the
public. Seating is limited and will be
provided only to the first 220 people
signing-in. All persons must sign-in
legibly.
Written Statements: Pursuant to 41
CFR 102–3.140, the public or interested
organizations may submit written
statements to the membership of the
Panel at any time or in response to the
stated agenda of a planned meeting.
Written statements should be submitted
to the Panel’s Designated Federal Officer
(DFO). The DFO’s contact information
can be obtained from the General
Services Administration’s Federal
Advisory Committee Act Database at
https://facadatabase.gov/. Written
statements that do not pertain to the
scheduled meeting of the Panel may be
submitted at any time. However, if
individual comments pertain to a
specific topic being discussed at a
planned meeting, then these statements
must be submitted no later than 5
business days prior to the meeting in
question. The DFO will review all
submitted written statements and
provide copies to all the committee
members.
Public Comments: In addition to
written statements, the Panel will set
aside 1 hour for individuals or
interested groups to address the Panel.
To ensure consideration of their
comments, individuals and interested
groups should submit written
statements as outlined in this notice; but
if they still want to address the Panel,
then they will be afforded the
opportunity to register to address the
Panel. The Panel’s DFO will have a
‘‘Sign-Up Roster’’ available at the Panel
meeting for registration on a first-come,
first-serve basis. Those wishing to
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
21811
address the Panel will be given no more
than 5 minutes to present their
comments, and at the end of the 1-hour
time period, no further public
comments will be accepted. Anyone
who signs-up to address the Panel, but
is unable to do so due to the time
limitation, may submit their comments
in writing; however, they must
understand that their written comments
may not be reviewed prior to the Panel’s
deliberation. To ensure timeliness of
comments for the official record, the
Panel encourages that individuals and
interested groups consider submitting
written statements instead of addressing
the Panel.
Dated: May 5, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2017–09450 Filed 5–9–17; 8:45 am]
BILLING CODE 5001–06–P
ENVIRONMENTAL PROTECTION
AGENCY
[EPA–HQ–OAR–2011–0742; FRL–9959–69–
OEI]
Information Collection Request
Submitted to OMB for Review and
Approval; Comment Request; Air
Pollution Regulations for Outer
Continental Shelf (OCS) Activities
Environmental Protection
Agency (EPA).
ACTION: Notice.
AGENCY:
The Environmental Protection
Agency (EPA) has submitted an
information collection request (ICR),
‘‘Air Pollution Regulations for Outer
Continental Shelf (OCS) Activities’’ to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act. This is a proposed
extension of the ICR. Public comments
were previously requested via the
Federal Register on May 29, 2015,
during a 60-day comment period. This
notice allows for an additional 30 days
for public comments. A fuller
description of the ICR is given below,
including its estimated burden and cost
to the public. An agency may not
conduct or sponsor and a person is not
required to respond to a collection of
information unless it displays a
currently valid OMB control number.
DATES: Additional comments may be
submitted on or before June 9, 2017.
ADDRESSES: Submit your comments,
referencing Docket ID No. EPA–HQ–
OAR–2011–0724, to (1) the EPA online
using https://www.regulations.gov (our
SUMMARY:
E:\FR\FM\10MYN1.SGM
10MYN1
Agencies
[Federal Register Volume 82, Number 89 (Wednesday, May 10, 2017)]
[Notices]
[Page 21811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09450]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Assistant Secretary of Defense (Health Affairs), Department of
Defense.
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The Department of Defense (DoD) is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
DATES: Open to the public Thursday, June 22, 2017 from 9:00 a.m. to
12:00 p.m.
ADDRESSES: The address of the open meeting is Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: Edward Norton, 703-681-2890 (Voice),
703-681-1940 (Facsimile), dha.ncr.health-it.mbx.baprequests@mail.mil
(Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls
Church, VA 22042-5101. Web site: https://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date
changes to the meeting agenda can be found on the Web site.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
Purpose of the Meeting: The Department of Defense is publishing
this notice to announce a Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as
the Panel).
Agenda:
1. Sign-In.
2. Welcome and Opening Remarks.
3. Public Citizen Comments.
4. Scheduled Therapeutic Class Reviews (Comments will follow each
agenda item).
a. Ophthalmic-1 Agents.
b. Pulmonary Miscellaneous.
5. Newly Approved Drugs Review.
6. Pertinent Utilization Management Issues.
7. Panel Discussions and Vote.
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and
the availability of space, this meeting is open to the public. Seating
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
Written Statements: Pursuant to 41 CFR 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel at any time or in response to the stated agenda
of a planned meeting. Written statements should be submitted to the
Panel's Designated Federal Officer (DFO). The DFO's contact information
can be obtained from the General Services Administration's Federal
Advisory Committee Act Database at https://facadatabase.gov/. Written
statements that do not pertain to the scheduled meeting of the Panel
may be submitted at any time. However, if individual comments pertain
to a specific topic being discussed at a planned meeting, then these
statements must be submitted no later than 5 business days prior to the
meeting in question. The DFO will review all submitted written
statements and provide copies to all the committee members.
Public Comments: In addition to written statements, the Panel will
set aside 1 hour for individuals or interested groups to address the
Panel. To ensure consideration of their comments, individuals and
interested groups should submit written statements as outlined in this
notice; but if they still want to address the Panel, then they will be
afforded the opportunity to register to address the Panel. The Panel's
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for
registration on a first-come, first-serve basis. Those wishing to
address the Panel will be given no more than 5 minutes to present their
comments, and at the end of the 1-hour time period, no further public
comments will be accepted. Anyone who signs-up to address the Panel,
but is unable to do so due to the time limitation, may submit their
comments in writing; however, they must understand that their written
comments may not be reviewed prior to the Panel's deliberation. To
ensure timeliness of comments for the official record, the Panel
encourages that individuals and interested groups consider submitting
written statements instead of addressing the Panel.
Dated: May 5, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2017-09450 Filed 5-9-17; 8:45 am]
BILLING CODE 5001-06-P